6Bast Rc Jr. Feeney M, Lazarus H, Reactivity of amonoclonal antibody with human ovarian carcinoma[J] .J Clin Invest, 1981,68:1331.
7Pabst T, Ludwig C, CA 125-a tumor marker[J]? Sehweiz Ned Woehenschr, 1995,125(24) : 1195.
8Duraker N,Hot S,Polat Y, Hobek A,et al.CEA,CA 19-9,and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice[J] .J Surg Oncol,2007,95(2) : 142.
9Kemer T, Ormen M, Kuralay F, et al. Diagnostic usefulness of carbohydrate antigen-125 in cancerous and noncancerous peritoneal effusions[J]. Tohoku J Exp Med,2005,205(1) : 11.
10Hayhurst A, Georgiou G. High-throughput antibody isolation [J]. Curr-Opin-Chem-Biol, 2001,5(6) : 683.
6Mirabeau-Beale KL,Kornblith AB,Penson RT,et al. Compar-ison of the quality of life of early and advanced stage ovariancancer survivors[J]. Gynecologic oncology, 2009,114(2) : 353-359.
7Tcherkassova J, Abramovich C,Moro R,et al. Combination ofCA125 and RECAF biomarkers for early detection of ovariancancer[J]. Tumour biology: the Journal of the InternationalSociety for Oncodevelopmental Biology and Medicine, 2011,32(4):831-838.
8Duffy Van Dalen A, Haglund C,et al. Tumour markers incolorectal cancer : European Group on Tumour Markers(EGTM) guidelines for clinical use[J]. Eur J Cancer, 2007,43(9):1348-1360.
9Yurkovetsky Z,Skates S,Lomakin A,et al. Development of amultimarker assay for early detection of ovarian cancer [J].Journal of Clinical Oncology: official journal of the AmericanSociety of Clinical Oncology,2010,28(13) :2159-2166.
